Published in Cancer Weekly, March 9th, 2004
Can-Fite develops innovative treatments for cancer and inflammatory diseases. The company is currently engaged in two multicenter phase II trials of its drug CF101 for the treatment of colorectal cancer and rheumatoid arthritis. It is also planning to initiate a phase I/II trial of CF101 in combination with chemotherapy in the U.S. in Q2 2004.
Palmer joins an existing U.S. management team that includes a VP of Drug Development, William Kerns, and a medical director, Michael H. Silverman....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.